SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994.
The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.
Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering - 3 September 2015
Acquisition Adds Global Rights to XEN45, a Minimally Invasive Best-In-Class Implantable Shunt for Glaucoma --- XEN45 Approved in Global Markets; Late-Stage Development in the US --- Bolsters Allergan's Development and Commercialization Position in Glaucoma
FDA Approval of ReShape Dual Balloon Marks Significant Step for the Weight Loss Program in Helping at Risk Group of Patients - 31 July 2015
Obesity is on the rise and is a worldwide epidemic. A recent Lancet study noted that the chance of an obese person becoming normal weight is less than .5%. Currently in the United States, the obese population outnumbers the overweight population. Bariatric surgery helps patients with severe obesity in terms of weight loss, reduction in severity and number of comorbid conditions. This week the U.S. Food and Drug Administration approved the ReShape Integrated Dual Balloon System (ReShape Dual Balloon) to treat obesity without the need for invasive surgery.